Skip to content

Efficacy of traditional Chinese medicine compound of Qi-Replenishing Blood-Activating and Stasis -Dissipating Lump-Softening on dysmenorrhea and focus debridement after high intensity focused ultrasound ablation for adenomyosis

Efficacy of traditional Chinese medicine compound of Qi-Replenishing Blood-Activating and Stasis -Dissipating Lump-Softening on dysmenorrhea and focus debridement after high intensity focused ultrasound ablation for adenomyosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001896
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis

Interventions

HIFU+Traditional Chinese Medicine:After HIFU ablation administer Traditional Chinese Medicine (TCM) with the therapeutic principle of "Tonifying Qi Activating Blood Circulation Resolving Blood Stasis
HIFU:Only HIFU ablation

Sponsors

Dongguan Nancheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Female aged between 20-55 years old; 2.Patients who meet the traditional Chinese medicine (TCM) and Western medical diagnostic criteria for adenomyosis and qualify for HIFU (High-Intensity Focused Ultrasound) surgery; 3.Patients who meet the diagnostic criteria for "Abdominal Mass" (Qi Deficiency and Blood Stasis Syndrome) in TCM; 4.Patients who have not recently participated in other clinical trials; 5.Patients who voluntarily agree to participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Diagnosed with other gynecological disorders (including but not limited to acute pelvic inflammatory disease etc.); 2.Severe organ dysfunction or inability to tolerate the treatment; 3.Abnormal cervical cytology findings; 4.Inability to fully comply with the treatment and follow-up examinations during the study period; 5.History of psychiatric disorders or current psychotic symptoms (e.g. schizophrenia mania depression etc.); 6.Hypertension arrhythmia or severe hepatic/renal dysfunction; 7.Participation in other clinical trials within the past 3 months; legal incapacity or restricted legal capacity; 8.Any other condition deemed by the investigator as unsuitable for trial participation.

Design outcomes

Primary

MeasureTime frame
Focus debridement;Menstrual flow;dysmenorrhea;

Secondary

MeasureTime frame
CA125;Interleukin-6;Uterine volume;Lesion volume;Glutamic pyruvic transaminase;Glutamic pyruvic transaminase;Blood routine;

Countries

China

Contacts

Public ContactTing Lin

Dongguan Nancheng Hospital

5577237@qq.com+86 136 0027 7938

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026